摘要
目的探讨罗格列酮对急性冠脉综合征患者超敏C反应蛋白(hs-CRP)的影响。方法将89例急性冠脉综合征患者随机分为治疗组47例和对照组42例,观察24周,治疗前后用乳胶增强免疫比浊法定量检测hs-CRP、P-选择素(Ps)及其他生化指标。结果与治疗前相比,治疗组hs-CRP、Ps明显降低(P<0.01);与对照组相比,治疗组hs-CRP、Ps的降低更明显,有显著性差异(P<0.05)。结论罗格列酮能降低急性冠脉综合征患者hs-CRP、Ps水平,起到抗炎及保护血管内皮功能的作用。
Objective It is to discuss the influence of rosiglitazone on high-sensitivity C - reactive protein （hs- CRP） in a- cute coronary syndrome （ACS） patients, Methods 89 patients with ACS were randomly divided into two groups. 47 patients were in treatment group and treated with rosiglitazone. The other 42 patients were in control group and treated regularly. The observation time was 12 weeks. The hs CRP, P - selectin （Ps） and other biochemical indexes were analyzed with emulsion enhanced immunoturbidimetry before and after treatment. Results Compared with that before treatment, the hs- CRP and Ps in treatment group obviously lowered （ P 〈 0.01）. Compared with control group, the hs CRP and Ps in treat- ment group lowered more obviously, and there was significant difference （P〈 0.05）. Conclusion Rosiglitazone can decrease the level of hs CRP and Ps in ACS patients. Therefore, it can inhibit inflammatory reactions and safeguard the function of the vessel endothelial cell.
出处
《现代中西医结合杂志》
CAS
2007年第29期4270-4271,共2页
Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词
罗格列酮
急性冠脉综合征
超敏C反应蛋白
P-选择素
rosiglitazone
acute coronary syndrome
high-sensitivity C-reactive protein
P-selectin
